Matthew Albert, MD, FACS, FASCRS

Medical Director, Surgical Innovation DHSI
AdventHealth
Orlando, FL, United States

Matthew Albert MD, FACS, FASCRS, Medical Director, Surgical Innovation, DHSI, AdventHealth Orlando
Tufts and UT Houston trained.
Founder of Central Florida Colon & Rectal Surgery group and ACGME accredited fellowship, AdventHealth Orlando Florida.
Developer TAMIS, Applied Gelpoint path
MIS colorectal surgery
Equal opportunist of platforms: Laparoscopic, Robotic, Hand assisted, Transanal, Endoluminal, whatever it takes.
Device Consulting: Laparoscopic, Robotic, and Endoscopic Platforms, Video, Instrumentation, Fluorescence, advanced imaging, AI in surgery.
Product Commercialization, strategy, surgical teaching and training, live surgical demonstration. Key opinion leaders
Consulting FDA 510K device clearance
Clinical trials: Principal Investigator, Astellas Phase 3 for ureteral identification, Endoquest Robotics, Endoluminal ESD, IDE pending
Disgruntled, cynic of current health care, desperate for retirement.

Disclosure information not submitted.

Presentation(s):

• VM53 - Redo Two Stage Turnbull-Cutait with Delayed Coloanal Anastomosis Using Indocyanine Green

  Saturday, June 1, 2024
  10:00 AM – 1:30 PM ET, USA

• eP209 - Is There a Role for Lateral Lymph Node Dissection in Locally Advanced Rectal Cancer? A Decision Tree Analysis

  Sunday, June 2, 2024
  8:36 AM – 8:41 AM ET, USA

• eP807 - Functional Outcomes after Transanal Total Mesorectal Excision (taTME) for Rectal Cancer: Results from the Phase II North American Multicenter Trial

  Monday, June 3, 2024
  10:54 AM – 10:59 AM ET, USA

• eP812 - A Phase 3, Multicenter, Open-Label, Randomized, Placebo-Controlled Trial, for Ureteral Identification Using Pudexacianinium Chloride (ASP5354) in Patients Undergoing Abdominopelvic Surgery

  Monday, June 3, 2024
  10:36 AM – 10:41 AM ET, USA